Compare Charles River Laboratories Intl. Inc (CRL) vs Global Payments Inc (GPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Global Payments Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $232.3 (market cap $11.14B), while Global Payments Inc trades at $78 (market cap $20.76B). The key difference: Global Payments Inc is the larger of the two by market cap, and Global Payments Inc pays a 1.32% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | GPN | |
|---|---|---|
Market Cap | $11.14B | $20.76B |
Sector | Health | Industrials |
52-Week High | $233.60 | $90.01 |
52-Week Low | $145.57 | $62.47 |
Enterprise Value | $14.00B | $38.48B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
GPN trades at $76.85, up 1.07% today, with a bullish technical signal from moving averages and recent earnings beats. The company reported Q1 2026 EPS of $2.96, exceeding expectations, and maintains strong cash flow from operations at $2.66B in 2025. However, net income margin turned negative at -7.97% for 2026, reflecting profitability challenges amid rising debt levels, with debt-to-asset ratio increasing to 41.57% in 2025.
The outlook is mixed: analyst consensus is bullish with a $81.56 price target and 58% buy ratings, supported by AI-driven POS expansions and the Worldpay integration. Key risks include margin pressure from fintech competition and high leverage, which could constrain equity returns if revenue growth falters.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →
